Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Novocure to $102 from $104 and keeps an Overweight rating on the shares. Novocure reported mixed Q2 results, with TRx and active patient volumes generally better than expected, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVCR: